Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $12.6 million.

  • Verrica Pharmaceuticals' Accumulated Expenses fell 3332.98% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 3332.98%. This contributed to the annual value of $13.5 million for FY2024, which is 251.8% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Accumulated Expenses stood at $12.6 million for Q3 2025, which was down 3332.98% from $13.1 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Accumulated Expenses high stood at $18.9 million for Q3 2024, and its period low was $1.8 million during Q1 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $3.9 million (2021), whereas its average is $8.3 million.
  • Per our database at Business Quant, Verrica Pharmaceuticals' Accumulated Expenses soared by 79626.27% in 2024 and then crashed by 3332.98% in 2025.
  • Verrica Pharmaceuticals' Accumulated Expenses (Quarter) stood at $3.3 million in 2021, then dropped by 18.71% to $2.7 million in 2022, then soared by 422.03% to $13.9 million in 2023, then dropped by 2.52% to $13.5 million in 2024, then fell by 6.74% to $12.6 million in 2025.
  • Its Accumulated Expenses was $12.6 million in Q3 2025, compared to $13.1 million in Q2 2025 and $14.5 million in Q1 2025.